Optomed

1.51 EUR

+1.07 %

5,666 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+1.07 %
-32.29 %
-43.55 %
-59.95 %
-58.80 %
-63.75 %
-53.96 %
-87.42 %
-67.03 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
32.39M EUR
Turnover
88.69K EUR
P/E (adj.) (26e)
-11.17
EV/EBIT (adj.) (26e)
-8.25
P/B (26e)
1.53
EV/S (26e)
1.55
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
2026-05-07
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-05-07

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14/8
2026

Interim report Q2'26

6/11
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Optomed Q4'25 förhandskommentar: Fokus på guidning
Analyst Comment by
Juha Kinnunen

Optomed Q4'25 förhandskommentar: Fokus på guidning

Optomed publicerar sin Q4-rapport nästa tisdag. Det största fokuset i bokslutet ligger på omsättningstillväxtprognosen för 2026, vilken vi förväntar oss vara i formen "växer starkt". Vårt fokus i rapporten ligger särskilt på den kommersiella utvecklingen av drivkrafterna för tillväxt inom segmentet Utrustning, såsom Aurora AEYE-lösningen och Optomed Lumo.

Optomed
Forum discussions
Apparently, projects are also being prepared in Portugal. Iiro, who is tagged in the post, is the ICT Manager at Optomed. Mona Health’s AI is likely being used. Image management is handled through Sectra. That pretty much puts the whole package together.
11 hours ago
by Sheikki
6
This caught my eye on LinkedIn. It might not necessarily belong in this thread, but at least to me, it’s a new Finnish innovation / company that “follows up” on Optomed’s retinal findings (Maculaser Oy). Maculaser – Pioneering retinal treatment
21 hours ago
by Fabbari
6
In ESG reporting, that “G” component probably causes the most to chew on. Environment and Social are a breeze for a health technology company, but as for point G: Optomed is a small company operating in a new industry with small revenue. If they need to take a stand on how the Governance...
8 hours ago
by Dr.Feelgood
4
I’ve been following this one. What exactly is this project? It’s unfamiliar to me, does anyone else have more information on this? LinkedIn #isight #inovação #saúdedigital #transformaçãodigital #inteligênciaartificial... Tive o privilégio de participar num projeto verdadeiramente...
19 hours ago
by Artoh1
4
It’s likely that this ESG reporting involves not just Optomed itself, but also the supply chain Optomed uses, which is why the overall timeline is not entirely in Optomed’s hands. As for Optomed itself, getting the reporting in order is unlikely to be a major issue.
20 hours ago
by Sheikki
3
It’s good that the much-maligned software side is also busy around the world. It’s a pity that at least on the table, a Canon CR-2 camera seems to be featured instead of Optomed hardware.
10 hours ago
2
You can certainly draw the conclusion from that material that Optomed has its foot in the door with AstraZeneca. Of course, there was a peculiar moment in the CEO’s recent interview; he couldn’t say / didn’t know the schedule for the ESG process, even though it concerns them directly...
yesterday
by kivimies
2
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.